Gossamer Bio (NASDAQ:GOSS) Now Covered by Chardan Capital

Stock analysts at Chardan Capital started coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating on the stock.

Several other brokerages have also weighed in on GOSS. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $256.00.

Gossamer Bio Trading Up 5.5%

Shares of Gossamer Bio stock traded up $0.52 during mid-day trading on Tuesday, reaching $9.79. 321,405 shares of the stock were exchanged, compared to its average volume of 241,562. Gossamer Bio has a fifty-two week low of $8.99 and a fifty-two week high of $309.60. The firm has a 50-day simple moving average of $12.34 and a 200 day simple moving average of $17.38. The company has a market cap of $59.85 million, a price-to-earnings ratio of -0.17 and a beta of 2.21.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC purchased a new position in shares of Gossamer Bio during the 2nd quarter worth approximately $35,000. Hsbc Holdings PLC bought a new position in Gossamer Bio in the first quarter worth approximately $38,000. SG Americas Securities LLC lifted its holdings in Gossamer Bio by 73.4% during the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock valued at $42,000 after purchasing an additional 54,439 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Gossamer Bio during the second quarter valued at approximately $65,000. Finally, Ieq Capital LLC bought a new stake in Gossamer Bio in the second quarter worth $97,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.